FDA RSABE & alpha inflation [RSABE / ABEL]

posted by Helmut Homepage – Vienna, Austria, 2015-02-03 13:22 (4157 d 17:55 ago) – Posting: # 14360
Views: 26,365

Dear Detlew,

❝ Did you consider the paper

Davit et al. (2012)

❝ in the pictures?


No.

❝ This paper wants us to neglect the discontinuity at CV~30% in looking at the GMR's we assume for bioinequivalence. Instead we are forced to look at widening implied limits from s0=0.25 on (CV~25.4%). Then the inflation at CV=30% hokus pokus vanishes.


I used

power.RSABE(CV=0.30, n=24, theta0=0.8,
            design="2x3x3", nsims=1e6)
[1] 0.116132


I don’t see the inflation vanishing. On the contrary:

power.RSABE(CV=se2CV(0.30), n=24, theta0=0.8,
            design="2x3x3", nsims=1e6)
[1] 0.126651


❝ BTW: Anybody out there to shed some light on the arguments of that paper?

❝ Desired consumer risk model (!), distinct from implementation ... :confused:


Not me. I’m :confused: as well…

❝ Is it sound or only an attempt to answer discussions about alpha-inflation?


Duno. Talked about the inflation of the TIE with Barbara – but in May 2013.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
147 visitors (1 registered, 146 guests [including 22 identified bots]).
Forum time: 08:18 CEST (Europe/Vienna)

Competence, like truth, beauty and contact lenses,
is in the eye of the beholder.    Laurence J. Peter

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5